On April 12, Jin10 reported that Johnson & Johnson announced the official launch of its innovative lung cancer treatment drug Ruko (Avelumab injection) in China. Ruko is administered in combination with carboplatin and pemetrexed and is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer confirmed to carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Johnson & Johnson announced the launch of Evusheld injection in China.
On April 12, Jin10 reported that Johnson & Johnson announced the official launch of its innovative lung cancer treatment drug Ruko (Avelumab injection) in China. Ruko is administered in combination with carboplatin and pemetrexed and is indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer confirmed to carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations.